Jim Simons’s American Renal Associates Holdings, Inc ARA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-824,675
| Closed | -$9.44M | – | 3910 |
|
|
2020
Q4 | $9.44M | Sell |
824,675
-293,000
| -26% | -$3.34M | 0.01% | 1211 |
|
|
2020
Q3 | $7.71M | Buy |
1,117,675
+27,800
| +3% | +$183K | 0.01% | 1310 |
|
|
2020
Q2 | $7.11M | Buy |
1,089,875
+30,600
| +3% | +$198K | 0.01% | 1417 |
|
|
2020
Q1 | $7M | Buy |
1,059,275
+22,575
| +2% | +$197K | 0.01% | 1373 |
|
|
2019
Q4 | $10.8M | Buy |
1,036,700
+91,725
| +10% | +$784K | 0.01% | 1400 |
|
|
2019
Q3 | $5.97M | Buy |
944,975
+306,015
| +48% | +$2.28M | 0.01% | 1691 |
|
|
2019
Q2 | $4.75M | Buy |
638,960
+177,100
| +38% | +$1.17M | ﹤0.01% | 1844 |
|
|
2019
Q1 | $2.84M | Sell |
461,860
-28,900
| -6% | -$335K | ﹤0.01% | 2131 |
|
|
2018
Q4 | $5.65M | Buy |
490,760
+32,960
| +7% | +$562K | 0.01% | 1639 |
|
|
2018
Q3 | $9.91M | Buy |
457,800
+110,300
| +32% | +$2.09M | 0.01% | 1365 |
|
|
2018
Q2 | $5.48M | Buy |
347,500
+183,000
| +111% | +$2.88M | 0.01% | 1730 |
|
|
2018
Q1 | $3.1M | Buy |
+164,500
| New | +$3.24M | ﹤0.01% | 2086 |
|
Jim Simons's ARA Position: Q1 2021 in Review
Jim Simons sold out of American Renal Associates Holdings, Inc (ARA) in Q1 2021, closing a stake of 824,675 shares — an estimated $9.44M sold.
Jim Simons first reported a position in ARA in Q1 2018 and held it in 12 quarters. The position peaked at $10.8M in Q4 2019. 0 funds tracked by Wall St. Rank hold ARA as of Q1 2021.
- Jim Simons reported no remaining American Renal Associates Holdings, Inc position as of Q1 2021 after selling out during the quarter.
- Jim Simons sold 824,675 American Renal Associates Holdings, Inc shares in Q1 2021, an estimated $9.44M.
- Jim Simons first reported a position in American Renal Associates Holdings, Inc in Q1 2018 and held it in 12 quarters.
- Jim Simons's American Renal Associates Holdings, Inc position peaked at $10.8M in Q4 2019.
- 0 funds tracked by Wall St. Rank held American Renal Associates Holdings, Inc as of Q1 2021.
Based on Renaissance Technologies's 13F filing for Q1 2021, filed 13 May 2021.